ArticleACS nano2015
Spatiotemporal Targeting of a Dual-Ligand Nanoparticle to Cancer Metastasis.
Article in ACS nano, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Precision nanomedicine for lung metastatic osteosarcoma: challenges, therapeutic strategies, and perspectives.Materials today. Bio · 2026Review
- Co-encapsulation of an AKT Inhibitor Enhances the Tumor-cell Selectivity of STING Agonists in Co-delivery Liposomes.Pharmaceutical research · 2025Article
- RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases.Pharmacological research · 2025Review
- Engineering supramolecular peptide nanofibers for in vivo platelet-hitchhiking beyond ligand-receptor recognition.Science advances · 2024Article
- Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges.International journal of nanomedicine · 2024Review
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells.Materials today. Bio · 2023Review
- Nanotechnology-aided advancement in the combating of cancer metastasis.Cancer metastasis reviews · 2022Review
- Comparison of the uptake of untargeted and targeted immunostimulatory nanoparticles by immune cells in the microenvironment of metastatic breast cancer.Journal of materials chemistry. B · 2022Article
- Hyperthermia-mediated changes in the tumor immune microenvironment using iron oxide nanoparticles.Nanoscale advances · 2021Article
- Quantitative analysis of metastatic breast cancer in mice using deep learning on cryo-image data.Scientific reports · 2021Article
- Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.International journal of molecular sciences · 2021Review
- Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.Blood · 2021Article
- Review
- The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chemical reviews · 2021Review
- Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance.Oncogene · 2021Review
- Biomedical nanoparticle design: What we can learn from viruses.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Targeting self-assembled F127-peptide polymer with pH sensitivity for release of anticancer drugs.RSC advances · 2021Article
- Investigation of Specific Targeting of Triptorelin-Conjugated Dextran-Coated Magnetite Nanoparticles as a Targeted Probe in GnRHContrast media & molecular imaging · 2021Article
- Targeting Selectins Mediated Biological Activities With Multivalent Probes.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Various targeting strategies and ligands have been employed to direct nanoparticles to tumors that upregulate specific cell-surface molecules. However, tumors display a dynamic, heterogeneous microenvironment, which undergoes spatiotemporal changes including the expression of targetable cell-surface biomarkers. Here, we investigated a dual-ligand nanoparticle to effectively target two receptors overexpressed in aggressive tumors. By using two different chemical specificities, the dual-ligand strategy considered the spatiotemporal alterations in the expression patterns of the receptors in cancer sites. As a case study, we used two mouse models of metastasis of triple-negative breast cancer using the MDA-MB-231 and 4T1 cells. The dual-ligand system utilized two peptides targeting P-selectin and αvβ3 integrin, which are functionally linked to different stages of the development of metastatic disease at a distal site. Using in vivo multimodal imaging and post mortem histological analyses, this study shows that the dual-ligand nanoparticle effectively targeted metastatic disease that was otherwise missed by single-ligand strategies. The dual-ligand nanoparticle was capable of capturing different metastatic sites within the same animal that overexpressed either receptor or both of them. Furthermore, the highly efficient targeting resulted in 22% of the injected dual-ligand nanoparticles being deposited in early-stage metastases within 2 h after injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.